Senior Scientific Director
Novo Nordisk
Virum, Hovedstaden, Denmark
Rune Overgaard is a senior scientific director in pharmacometrics at Novo Nordisk, with overall responsibility for pharmacometrics modelling across the Obesity and Type 2 diabetes portfolio. Rune has been employed at Novo Nordisk for 20 years, with contributions across most therapy areas addressed by Novo Nordisk, and is currently part of the pharmacometrics leadership team.
Recently, Rune has been directly involved in the amycretin and the oral semaglutide projects, with a focus on dose selection and translation of internal and external data across trial designs and populations. And further to support the application of modelling to create pivotal evidence for health authority assessments to replace direct evidence from clinical trials.
Rune has a background in high energy physics from the Niels Bohr Institute at the University of Copenhagen, with a Ph.D. in pharmacometrics with affiliation to departments of applied statistics and pharmaceutical sciences.
Disclosure information not submitted.
Sunday, October 19, 2025
11:00 AM - 12:30 PM MDT
MIDD for semaglutide – contributions from different modelling approaches throughout the value chain
Sunday, October 19, 2025
11:22 AM - 11:45 AM MDT